EcoVadis Platinum Level Achieved in 2026
We have renewed our EcoVadis assessment and achieved the Platinum level!
Press releases
March 10, 2022
GelMEDIX
This partnership represents the first equity investment of the incubator created by HTL to accelerate the development of innovative treatments using biopolymers in therapeutic areas with unmet medical needs.
HTL will provide financial, industrial and scientific support to GelMEDIX to facilitate the development of next generation ocular and regenerative therapies based on its proprietary hydrogel platform.
This platform enables the delivery of therapeutics from small molecules to cell and gene therapies.
To see our most recent news,
follow us on LinkedIn
Read more
news from us
-
Articles April 13, 2026EcoVadis Platinum Level Achieved in 2026
We have renewed our EcoVadis assessment and achieved the Platinum level!
-
Articles March 19, 2026HTL Biotechnology at PCHi 2026 in Hangzhou
HTL Biotechnology recently took part in PCHi (Personal Care and Homecare Ingredients), one of the leading events for the personal care industry, held in Hangzhou, China.
-
Articles February 16, 2026Lunar New Year 2026: Entering the Year of the Fire Horse
From 17 February, we celebrate the Lunar New Year and step into the Year of the Fire Horse — a powerful symbol of drive, resilience, and forward momentum across Asia.
A time of renewal, ambition, and fresh opportunities for growth.